Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
- Authors: Krivorotko PV1, Burdaeva ON2, Nechaeva MN2, Frolova MA3, Kopp MV4, Abrosimova AA5, Ivanov RA5
-
Affiliations:
- N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation
- Arkhangelsk Clinical Oncology Dispensary
- N.N.Blokhin Russian Cancer Research Center
- Samara Regional Clinical Oncology Center
- CJSC "Biocad"
- Issue: Vol 17, No 2 (2015)
- Pages: 45-52
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27010
- ID: 27010
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
P V Krivorotko
N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federationд-р мед. наук, глав. науч. сотр., зав. клин. отд-нием опухолей молочной железы ФГБУ НИИ онкологии им. Н.Н.Петрова 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68
O N Burdaeva
Arkhangelsk Clinical Oncology Dispensaryзав. химиотерапевтическим отд-нием ГБУ АО АКОД 163045, Russian Federation, Arkhangelsk, pr. Obvodnyi kanal, d. 145, korp. 1
M N Nechaeva
Arkhangelsk Clinical Oncology Dispensaryврач отд-ния химиотерапии ГБУ АО АКОД 163045, Russian Federation, Arkhangelsk, pr. Obvodnyi kanal, d. 145, korp. 1
M A Frolova
N.N.Blokhin Russian Cancer Research Centerканд. мед. наук, ст. науч. сотр. ФГБНУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
M V Kopp
Samara Regional Clinical Oncology Centerд-р мед. наук, проф., руководитель отделения химиотерапии №1 Самарского областного клинического онкологического диспансера 443031, Russian Federation, Samara, ul. Solnechnaia, d. 50
A A Abrosimova
CJSC "Biocad"мед. эксперт II категории ЗАО «Биокад» 198515, Russian Federation, Saint Petersburg, ul. Sviazi, 34a
R A Ivanov
CJSC "Biocad"
Email: ivanov@biocad.ru
зам. ген. дир. по биомедицинским исследованиям и развитию ЗАО «Биокад» 198515, Russian Federation, Saint Petersburg, ul. Sviazi, 34a
References
- Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями. Вестн. РОНЦ им. Н.Н.Блохина. 2010; 21 (2. Прил. 1).
- Bronchud M.H, Potter M.R, Morgenstern G et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colony - stimulating factor in patients. Br J Cancer 1988; 58: 64-9.
- Lord B.I, Bronchud M.H, Owens S et al. The kinetics of human granulopoiesis following treatment with granulocyte colony - stimulating factor in vivo. PNAS 1989; 86: 9499-503.
- Yamamoto Y, Klein T.W, Friedman H et al. Granulocyte colony - stimulating factor potentiates emu-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol Med Microbiol 1993; 7: 15-22.
- Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony - stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991; 325: 164-70.
- Trillet-Lenoir V, Green J, Manegold С et al. Recombinant granulocyte colony - stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319-24.
- Welte К, Reiter A, Mempel К et al. A randomized phase-Ill study of the efficacy of granulocyte - colony stimulating factor in children with high - risk acute lymphoblastic leukemia. Blood J 1996; 87: 3143-50.
- Holmes F.A, O'Shaughnessy J.A, Vukelja S. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high - risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20 (3): 727-31.
- Vogel C.L, Wojtukiewicz M.Z, Carroll R. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double blind, placebo - controlled phase III study. J Clin Oncol 2005; 23 (6): 1178-84.
- Johnston E, Crawford J, Blackwell S. Randomized, dose - escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18 (13): 2522-8.